Navigation Links
Frederick R. Appelbaum, M.D. and Ross C. Donehower, M.D. Join Scientific Advisory Board of Celator(R) Pharmaceuticals
Date:11/28/2007

Renowned oncologists bring decades of cancer research and clinical

development experience to Celator.

PRINCETON, N.J., Nov. 28 /PRNewswire/ -- Celator Pharmaceuticals, a biotechnology company working to develop combination chemotherapies to treat different types of cancer, today announced two recent appointments to its Scientific Advisory Board: Frederick R. Appelbaum, M.D., head of the University of Washington School of Medicine's Division of Medical Oncology and President of the Seattle Cancer Care Alliance (SCCA); and Ross C. Donehower, M.D., Professor of Oncology and Medicine at The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins University School of Medicine.

Dr. Appelbaum is the author of more than 800 articles and is active on the editorial boards of many scientific journals. He is a current or former member of a number of national scientific committees including the Board of Scientific Advisors of the National Cancer Institute. Dr. Appelbaum is a graduate of Dartmouth College and of Tufts University School of Medicine. Prior to joining the faculty of the University of Washington in 1978, Dr. Appelbaum was a clinical associate and investigator with the National Cancer Institute in Bethesda, MD.

Dr. Donehower is also Director of the Division of Medical Oncology at The Johns Hopkins Oncology Center. His clinical research has focused on the treatment of gastrointestinal and lung cancers as well as new drug development. He has authored over 150 scientific publications and sits on the editorial board of numerous prestigious scientific journals. Before joining Johns Hopkins, Dr. Donehower was a surgeon with the U.S. Public Health Service and a clinical associate with the National Cancer Institute. Dr. Donehower received his medical training at the University of Minnesota.

"We are delighted to welcome Dr. Appelbaum and Dr. Donehower to Celator's Scientific Advisory Board," said Andrew Janoff, Ph.D., CEO of Celator Pharmaceuticals. "Both of these talented individuals bring a depth of experience in cancer research and treatment that will be an enormous strategic asset for us as we work to develop new and more effective combination chemotherapies in the years ahead based on Celator's Ratiometric Dosing(TM) process."

About Celator

Celator Pharmaceuticals, Inc., is a privately held biopharmaceutical company working to develop new and more effective therapies to treat cancer. CombiPlex(TM), the company's technology platform, represents a revolutionary new approach to the development of combination therapies based on the principle of ratiometric dosing, where drug agents are combined and maintained in the optimal ratio to target cancer cells with maximum effectiveness. The company pipeline includes: CPX-1, currently in a Phase 2 trial as a treatment option for colorectal cancer; CPX-351, currently in a Phase 1 trial as a treatment for leukemia (for information visit http://www.clinicaltrials.gov and search "Celator"); CPX-571, now positioned to advance to a Phase 1 trial and targeting small cell lung cancer; and multiple early stage pre-clinical development programs. Based on the applications of CombiPlex, Celator is positioned to advance a broad pipeline of combination therapies involving both previously approved and novel drug agents.


'/>"/>
SOURCE Celator Pharmaceuticals
Copyright©2007 PR Newswire.
All rights reserved

Related medicine news :

1. Frederick J. Ferrer Named New CEO of The Health Trust
2. Milestone Scientific Announces Successful Completion of its Collaboration Agreement With Carticept Medical
3. Thomson Scientific Predicts Nobel Laureates
4. Genaera Announces Formation of Scientific Advisory Board for Obesity Drug Candidate Trodusquemine (MSI-1436)
5. Thomson Scientific Announces BONDplus for Biological Researchers
6. Milestone Scientific Commences Declaratory Judgment Action With Respect to Its Single Tooth Anesthesia (STA(TM)) System and Compudent(TM) System
7. International Society of Hair Restoration Surgery Hosts 15th Annual Scientific Meeting in Las Vegas, September 26-30, 2007
8. Milestone Scientific Names Robert Presutti New Vice President of Sales and Marketing
9. Thomson Scientific Signs Multi-Year Agreement with The Council for Scientific and Industrial Research (CSIR)
10. Heart Failure Society of America 11th Annual Scientific Meeting to Focus on Heart Failure Guidelines, Innovation and New Research
11. Milestone Scientific to Exhibit the STA(TM) System at the American Dental Associations 148th Annual Session in San Francisco
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/20/2017)... Raton (PRWEB) , ... September 20, 2017 , ... In ... Daily Brain Booster has already been receiving positive feedback from customers trying the product ... months. , Daily Brain Booster was developed by neurosurgeon Shawn Moore, MD, for ...
(Date:9/20/2017)... , ... September 20, 2017 , ... ... of older Americans at risk of price gouging for their prescription drugs, according ... (TSCL) . “Because Medicare isn’t negotiating on our behalf, there’s no consistency in ...
(Date:9/20/2017)... ... September 20, 2017 , ... ... “RECYCLED Ezekiel's Plan for Freedom from ADDICTION” is the creation of published ... the field of addiction and homeless services, including more than a decade of ...
(Date:9/20/2017)... ... ... “Psalms of Humidity”: is a fascinating depiction of daily struggles and the ... closer to God. “Psalms of Humidity” is the creation of published author, David Waldrop, ... his life are the very same things that have shaped him into the man ...
(Date:9/20/2017)... (PRWEB) , ... September 20, 2017 , ... “Monique”: ... into uncomfortable situations. “Monique” is the creation of published author, Colleen Crispi, has owned ... Since then Crispi has been involved in real estate and cooking. , “The ...
Breaking Medicine News(10 mins):
(Date:9/18/2017)... Mich. , Sept. 18, 2017  PMD Healthcare ... Specialty Pharmacy of Kalamazoo, Mich. , ... hub service that expedites and streamlines patient and provider ... PD 2.0, and wellness management services.  ... device used to measure lung function for a variety ...
(Date:9/12/2017)... LAKES, N.J. , Sept. 12, 2017  Consumer reviews on ... Embrace Hearing as the number one company for hearing aids, ... ReSound™ and fifteen other brands. ... Embrace Hearing Named #1 by Consumers For Hearing Aids ... Embrace Hearing is an online store that provides ...
(Date:9/9/2017)...  Eli Lilly and Company (NYSE: LLY ... for lasmiditan, an investigational, oral, first-in-class molecule for the ... compared to placebo in the Phase 3 SPARTAN study. ... Congress of the International Headache Society (IHC) in ... today demonstrate lasmiditan,s potential to reduce pain and provide ...
Breaking Medicine Technology: